NYSE:GSK - GlaxoSmithKline Stock Price, Forecast & News

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

GlaxoSmithKline announced a quarterly dividend on Friday, May 3rd. Shareholders of record on Friday, May 17th will be given a dividend of $0.4953 per share on Thursday, July 11th. This represents a $1.98 dividend on an annualized basis and a yield of 4.15%. The ex-dividend date of this dividend is Thursday, May 16th. View GlaxoSmithKline's Dividend History.

GlaxoSmithKline plc (NYSE:GSK) issued its earnings results on Wednesday, October, 30th. The pharmaceutical company reported $0.95 EPS for the quarter, topping the Zacks' consensus estimate of $0.85 by $0.10. The pharmaceutical company earned $11.57 billion during the quarter, compared to analyst estimates of $11.34 billion. GlaxoSmithKline had a return on equity of 92.73% and a net margin of 13.76%. View GlaxoSmithKline's Earnings History.

GlaxoSmithKline is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for GlaxoSmithKline.

12 analysts have issued 12-month target prices for GlaxoSmithKline's stock. Their forecasts range from $45.00 to $53.00. On average, they expect GlaxoSmithKline's share price to reach $49.00 in the next twelve months. This suggests a possible upside of 2.5% from the stock's current price. View Analyst Price Targets for GlaxoSmithKline.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 2 sell ratings, 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GlaxoSmithKline.

News headlines about GSK stock have been trending somewhat positive on Wednesday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GlaxoSmithKline earned a news impact score of 1.0 on InfoTrie's scale. They also assigned media headlines about the pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for GlaxoSmithKline.

GlaxoSmithKline saw a increase in short interest in the month of December. As of December 13th, there was short interest totalling 7,110,000 shares, an increase of 6.0% from the November 28th total of 6,710,000 shares. Based on an average daily volume of 2,680,000 shares, the short-interest ratio is presently 2.7 days. Currently, 0.3% of the company's stock are sold short. View GlaxoSmithKline's Current Options Chain.

Some companies that are related to GlaxoSmithKline include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Eli Lilly And Co (LLY), AstraZeneca (AZN), AbbVie (ABBV), Sanofi (SNY), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Bayer (BAYRY) and Celgene (CELG).

Based on aggregate information from My MarketBeat watchlists, some companies that other GlaxoSmithKline investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Bank of America (BAC), Johnson & Johnson (JNJ), Intel (INTC), General Electric (GE) and Exxon Mobil (XOM).

GlaxoSmithKline's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Janney Montgomery Scott LLC (0.02%), Janney Capital Management LLC (0.02%), Chemung Canal Trust Co. (0.01%), Hennessy Advisors Inc. (0.00%), Farmers Trust Co. (0.00%) and Ipswich Investment Management Co. Inc. (0.00%). View Institutional Ownership Trends for GlaxoSmithKline.

GSK stock was sold by a variety of institutional investors in the last quarter, including Janney Capital Management LLC, Farmers Trust Co., Zeke Capital Advisors LLC, Hennessy Advisors Inc., Fluent Financial LLC, Mountain Capital Investment Advisors Inc, CENTRAL TRUST Co and Chemung Canal Trust Co.. View Insider Buying and Selling for GlaxoSmithKline.

GSK stock was bought by a variety of institutional investors in the last quarter, including Mainstay Capital Management LLC ADV, Janney Montgomery Scott LLC, Boenning & Scattergood Inc., Optimum Investment Advisors, AE Wealth Management LLC, Curbstone Financial Management Corp, OLD National Bancorp IN and Ingalls & Snyder LLC. View Insider Buying and Selling for GlaxoSmithKline.

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GSK stock can currently be purchased for approximately $47.79.

GlaxoSmithKline has a market capitalization of $119.20 billion and generates $41.14 billion in revenue each year. The pharmaceutical company earns $4.84 billion in net income (profit) each year or $3.16 on an earnings per share basis. GlaxoSmithKline employs 95,490 workers across the globe.View Additional Information About GlaxoSmithKline.

The official website for GlaxoSmithKline is http://www.gsk.com/.

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]